<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340597</url>
  </required_header>
  <id_info>
    <org_study_id>F901318-01-13-17</org_study_id>
    <nct_id>NCT03340597</nct_id>
  </id_info>
  <brief_title>Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects</brief_title>
  <official_title>A Phase I, Open Label Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Varying Oral Dosing Regimens for F901318</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>F2G Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>F2G Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, open label study evaluating safety, tolerability and pharmacokinetics of F901318
      in healthy subjects following up to 28 days dosing, where F901318 is given orally . The
      effect of food upon the pharmacokinetics of F901318 and the effect of F901318 upon the
      pharmacokinetics of midazolam will also be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each cohort will comprise 12 healthy subjects and cohorts A1 (A2), B1 and B2 will be
      conducted in a sequential manner such that the dose level can be optimised upon review of
      emerging safety, tolerability and PK data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Actual">April 13, 2018</completion_date>
  <primary_completion_date type="Actual">April 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>18 days</time_frame>
    <description>safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) 0-tau for F901318</measure>
    <time_frame>11 days</time_frame>
    <description>Pharmacokinetics (PK) of oral doses of F90318</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum plasma concentration (Cmax) for F901318</measure>
    <time_frame>11 days</time_frame>
    <description>PK of oral doses of F90318</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minimum plasma concentration (Cmin) for F901318</measure>
    <time_frame>11 days</time_frame>
    <description>PK of oral doses of F90318</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Invasive Aspergillosis</condition>
  <arm_group>
    <arm_group_label>A1; F901318 (10 days)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F901318 : 10 days dosing orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2; F901318</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F901318 : 10 days dosing orally, alternative dosing regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3; F901318</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F901318 : 10 days dosing orally, alternative dosing regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4; F901318</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F901318 : 10 days dosing orally, alternative dosing regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F901318</intervention_name>
    <description>F901318 tablet</description>
    <arm_group_label>A1; F901318 (10 days)</arm_group_label>
    <arm_group_label>A2; F901318</arm_group_label>
    <arm_group_label>A3; F901318</arm_group_label>
    <arm_group_label>A4; F901318</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be males or females of any ethnic origin between 18 and 55 years of age,
             weighing between 60 and 100 kg, with a body mass index (BMI) between 18 and 30 kg/m2.

          -  Subjects must be in good health, as determined by a medical history, physical
             examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations
             (congenital non-haemolytic hyperbilirubinaemia is not acceptable)

          -  Male subjects and female subjects of childbearing potential must agree to use
             appropriate contraception from screening, during the study and for 3 months after the
             last dose of study drug

        Exclusion Criteria:

          -  Female subjects who are pregnant or lactating.

          -  Subjects who have received any prescribed systemic or topical medication (other than
             hormonal contraception or hormone replacement therapy) within 14 days of the dose
             administration unless in the opinion of the Investigator and the medical monitor the
             medication will not interfere with the study procedures or compromise safety.

          -  Subjects who have used any non-prescribed systemic or topical medication (including
             herbal remedies) within 7 days of the dose administration (with the exception of
             vitamin/mineral supplements) unless in the opinion of the Investigator and the medical
             monitor the medication will not interfere with the study procedures or compromise
             safety.

          -  Subjects who have received any medications, including St John's Wort, known to
             chronically alter drug absorption or elimination processes within 30 days of the dose
             administration unless in the opinion of the Investigator and the medical monitor the
             medication will not interfere with the study procedures or compromise safety.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Bush, MB ChB PhD MRCS FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance CRU Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>July 31, 2018</last_update_submitted>
  <last_update_submitted_qc>July 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olorofim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

